3. Zyprexa - Top 10 Warnings and Recalls

Drug: Zyprexa

2006 sales: $4.4 billion

Manufacturer: Eli Lilly

Safety concern: Warning; weight gain, metabolic problems

Related Articles:
> Lilly strengthens Zyprexa warnings. Report
> Study: 86% of docs cut Zyprexa use. Report
> Lilly to pay $500M to settle Zyprexa claims. Report
> Lilly ignored Zyprexa safety data on weight, blood sugar. Report
> Lilly accused of promoting off-label Zyprexa use. Report
> NYT accuses Lilly of hiding safety problems. Report

3. Zyprexa - Top 10 Warnings and Recalls
Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.